CA-ESRI
10.3.2022 14:02:10 CET | Business Wire | Press release
Governments and businesses across the world are pledging to adopt more sustainable and equitable practices. Many are also working to limit activities that contribute to climate change. To support these efforts, Esri , the global leader in location intelligence, in partnership with Impact Observatory and Microsoft, is releasing a globally consistent 2017–2021 global land-use and land-cover map of the world based on the most up-to-date 10-meter Sentinel-2 satellite data. In addition to the new 2021 data, 10-meter land-use and land-cover data for 2017, 2018, 2019, and 2020 is included, illustrating five years of change across the planet.
This digital rendering of earth's surfaces offers detailed information and insights about how land is being used. The map is available online to more than 10 million users of geographic information system (GIS) software through Esri's ArcGIS Living Atlas of the World , the foremost collection of geographic information and services, including maps and apps.
"Accurate, timely, and accessible maps are critical for understanding the rapidly changing world, especially as the effects of climate change accelerate globally," said Jack Dangermond, Esri founder and president. "Planners worldwide can use this map to better understand complex challenges and take a geographic approach to decisions about food security, sustainable land use, surface water, and resource management."
Esri released a 2020 global land-cover map last year as well as a high-resolution 2050 global land-cover map , showing how earth's land surfaces might look 30 years from now. With the planned annual releases, users will have the option to make year-to-year comparisons for detecting change in vegetation and crops, forest extents, bare surfaces, and urban areas.
These maps also provide insights about locations with distinctive land use/land cover, as well as human activity affecting them. National government resource agencies use land-use/land-cover data as a basis for understanding trends in natural capital, which helps define land-planning priorities and determine budget allocations.
Esri's map layers were developed with imagery from the European Space Agency (ESA) Sentinel-2 satellite, with machine learning workflows by Esri Silver partner Impact Observatory and incredible compute resources from longtime partner Microsoft. The Sentinel-2 satellite carries a range of technologies including radar and multispectral imaging instruments for land, ocean, and atmospheres, enabling it to monitor vegetation, soil and water cover, inland waterways, and coastal areas.
"World leaders need to set and achieve ambitious targets for sustainable development and environmental restoration," said Steve Brumby, Impact Observatory cofounder and CEO. "Impact Observatory [and] our partners Esri and Microsoft are once again first to deliver an annual set of global maps at unprecedented scale and speed. These maps of changing land use and land cover provide leaders in governments, industry, and finance with a new AI [artificial intelligence]-powered capability for timely, actionable geospatial insights on demand."
Esri and Microsoft have released this 10-meter-resolution time-series map under a Creative Commons license to encourage broad adoption and ensure equitable access for planners working to create a more sustainable planet. Users can manipulate the map layers and other data layers with GIS software to create more dynamic visualizations.
In addition to being freely available in ArcGIS Online as a map service, these resources are also available for download and viewing. To explore the new 2021 global land-use/land-cover map, visit livingatlas.arcgis.com/landcover .
About Impact Observatory
Impact Observatory develops AI-powered, on-demand, geospatial data that maps changing land use and land cover at unprecedented scale and speed. Impact Observatory provides world leaders in governments, industry, and finance with timely, actionable, data-driven insights for sustainability and environmental risk analysis. Impact Observatory is a U.S. technology company based in Washington, D.C.
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2022 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005316/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
